Figure 5.

KLF5 was a target of miR-182-5p. (A) QRT-PCR assay for KLF5 mRNA expression in serum samples of atherosclerosis patients and healthy volunteers (n=45). Unpaired t-test was used to compare data with normal distribution and equal variance between two groups. (B and C) QRT-PCR and western blot assays for KLF5 mRNA (B) and protein (C) expression in HUVSMCs treated with 0 μg/mL, 25 μg/mL, 50 μg/mL or 75 μg/mL ox-LDL for 0 h, 6 h, 12 h, 24 h or 48 h. One-way ANOVA was applied for comparison of data among multiple groups, followed by Tukey’s post hoc test. Repeated measures of ANOVA were applied for comparison of data at different time points, followed by Bonferroni post hoc test. (D) Pearson correlation analysis for the correlation between the expression levels of miR-182-5p and KLF5 mRNA in serum samples of atherosclerosis patients (r=-0.5014, P < 0.001). (E) Dual-luciferase reporter assay for the luciferase activity of 293T cells in KLF5 3’UTR wt and KLF5 3’UTR mut groups. Unpaired t-test was used to compare data with normal distribution and equal variance between two groups. (F) RNA pull-down assay for the binding ability between miR-182-5p and KLF5 in HUVSMCs. Unpaired t-test was used to compare data with normal distribution and equal variance between two groups. *P < 0.05.